New Delhi: In a latest growth, a study carried out by Clinical Infectious Diseases in collaboration with National Institute of Virology and Indian Council of Medical Research (ICMR) has revealed that the ‘made in India’ COVID-19 vaccine, which is Bharat Biotech’s Covaxin, produces neutralising titres against all new key variants of COVID-19 together with the double mutant pressure B.1.617 and B.1.1.7.
The peer-review publication, Clinical Infectious Diseases, on Sunday (May 16, 2021) revealed the findings of the new study. The publication wrote, “Vaccination with Covaxin produced neutralising titres against all key emerging variants tested, including B.1.617 and B.1.1.7, first identified in India and the UK, respectively.”
The study additionally discovered no distinction in neutralisation between the UK variant and the vaccine pressure (D614G).
“A modest reduction in neutralisation by a factor of 1.95 was observed against the B.1.617 variant compared to vaccine variant (D614G),” the manuscript stated.
“No difference in neutralisation between B.1.1.7 (first isolated in the UK) and vaccine strain (D614G) was observed,” the manuscript added.
Earlier, Union Health Minister Dr. Harsh Vardhan had additionally defined that Covaxin is extra prone to work against newer variants just like the UK variant and the double mutation (Indian variant, B.1.617).
About Covaxin
India-based Covaxin is an inactivated vaccine, which is made up of killed coronaviruses. Bharat Biotech used a pattern of the coronavirus, remoted by India’s National Institute of Virology, to develop this vaccine. When administered, Covaxin immune cells can nonetheless recognise the useless virus, prompting the immune system to make antibodies against the pandemic virus.
This vaccine works by educating the immune system to make antibodies against the SARS-CoV-2 coronavirus.
Bharat Biotech to share Covaxin method with different producers
The main drug maker Bharat Biotech is able to share the method of its anti-COVID vaccine Covaxin with different producers. NITI Aayog member Dr VK Paul knowledgeable that ‘Bharat Biotech has welcomed this choice’ on Thursday (May 13, 2021).
Dr. VK Paul reportedly stated, “People say that Covaxin be given to other companies for manufacturing. I am happy to say that Covaxin manufacturing company (Bharat Biotech) has welcomed this when we discussed it with them. Under this vaccine, live virus is inactivated & this is done only in BSL3 labs.”
